Research and Development

Dr Yvonne Greenstreet has joined Pfizer to head up medicines development for its Specialty Care business unit. She moves to …

Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

Science minister David Willetts says the government will do all it can to maintain pharma research in Kent, after Pfizer …

Cuts to government funding for research in universities have been condemned by the UK’s top centres of learning. The government …

Pfizer has announced that it is to close its UK research site at Sandwich in Kent, with the loss of …

The NHS campaign to vaccinate girls against the future risk of developing cervical cancer has been a success, according to …

Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …

The European Medicines Agency is to prioritise issues such as pharmacovigilance over the next five years, while also looking closely …

Almirall has appointed Bertil Lindmark as executive director of R&D following the retirement of Dr Per-Olof Andersson. Bertil joins the …

Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …

The regulatory landscape can change in a very short period of time. Matthew Walker, Senior Regulatory Affairs Executive at TRAC …

Research and development partnerships between big pharma and the biotech sector are now a vital component in bringing new medicines …

Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …

German clinical research company AiCuris has appointed Dr Marie-Paule Richard as chief medical officer. She has over 24 years of …